Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.
Heo M, Norton BL, Pericot-Valverde I, Mehta SH, Tsui JI, Taylor LE, Lum PJ, Feinberg J, Kim AY, Arnsten JH, Sprecht-Walsh S, Page K, Murray-Krezan C, Anderson J, Litwin AH; HERO Study Group. Heo M, et al. Among authors: lum pj. J Hepatol. 2024 May;80(5):702-713. doi: 10.1016/j.jhep.2023.12.020. Epub 2024 Jan 17. J Hepatol. 2024. PMID: 38242324
Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study.
Pericot-Valverde I, Lopes SS, Nahvi S, Thrasher JF, Karasz A, Taylor LE, Mehta SH, Lum PJ, Tsui JI, Page K, Feinberg J, Kim AY, Norton BL, Arnsten JH, Fernandez-Artamendi S, Heo M, Litwin A; HERO Research Group. Pericot-Valverde I, et al. Among authors: lum pj. Open Forum Infect Dis. 2023 Oct 5;10(11):ofad498. doi: 10.1093/ofid/ofad498. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38023556 Free PMC article.
Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: The HERO study.
Lopes SS, Pericot-Valverde I, Arnsten J, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Moschella P, Heo M, Litwin AH. Lopes SS, et al. Among authors: lum pj. Int J Drug Policy. 2024 Jan;123:104288. doi: 10.1016/j.drugpo.2023.104288. Epub 2023 Dec 15. Int J Drug Policy. 2024. PMID: 38103458 Clinical Trial.
Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study.
Lopes SS, Pericot-Valverde I, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Karasz A, Arnsten J, Moschella P, Heo M, Litwin AH. Lopes SS, et al. Among authors: lum pj. BMC Infect Dis. 2024 Feb 23;24(1):251. doi: 10.1186/s12879-024-09124-3. BMC Infect Dis. 2024. PMID: 38395747 Free PMC article.
A Video-Observed Treatment Strategy to Improve Adherence to Treatment Among Persons Who Inject Drugs Infected With Hepatitis C Virus: Qualitative Study of Stakeholder Perceptions and Experiences.
Karasz A, Merchant K, Arnsten J, Feinberg J, Kim AY, Lum PJ, McKee MD, Mehta SH, Meissner P, Norton BL, Page K, Pericot-Valverde I, Singh R, Stein E, Taylor LE, Tsui JI, Wagner K, Litwin A. Karasz A, et al. Among authors: lum pj. J Med Internet Res. 2023 Jun 2;25:e38176. doi: 10.2196/38176. J Med Internet Res. 2023. PMID: 37266986 Free PMC article.
Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs.
Tsui JI, Lum PJ, Taylor LE, Mehta SH, Feinberg J, Kim AY, Norton BL, Niu J, Heo M, Arnsten J, Pericot-Valverde I, Thomas A, Blalock KL, Radick A, Murray-Krezan C, Page K, Litwin AH; HERO Study Group. Tsui JI, et al. Among authors: lum pj. Drug Alcohol Depend. 2023 Jun 1;247:109878. doi: 10.1016/j.drugalcdep.2023.109878. Epub 2023 Apr 17. Drug Alcohol Depend. 2023. PMID: 37150144 Clinical Trial.
Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial.
Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Heo M, Arnsten J, Meissner P, Karasz A, Mckee MD, Ward JW, Johnson N, Pericot-Valverde I, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Roche J, Murray-Krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Page K; HERO Study Group. Litwin AH, et al. Among authors: lum pj. Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1112-1127. doi: 10.1016/S2468-1253(22)00275-8. Lancet Gastroenterol Hepatol. 2022. PMID: 36370741 Clinical Trial.
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Korthuis PT, Cook RR, Lum PJ, Waddell EN, Tookes H, Vergara-Rodriguez P, Kunkel LE, Lucas GM, Rodriguez AE, Bielavitz S, Fanucchi LC, Hoffman KA, Bachrach K, Payne EH, Collins JA, Matthews A, Oden N, Jacobs P, Jelstrom E, Sorensen JL, McCarty D. Korthuis PT, et al. Among authors: lum pj. Addiction. 2022 Jul;117(7):1961-1971. doi: 10.1111/add.15836. Epub 2022 Mar 2. Addiction. 2022. PMID: 35129242 Free PMC article. Clinical Trial.
71 results